Avaulta Mesh: Patients Are Not the Women They Once Were Washington, DC: Avaulta mesh is but one player in a women's health issue that, to some in the legal profession, represent a particularly alarming portfolio that sees many patients no longer existing as the women they once were. In the absence of an Avaulta mesh recall, the FDA announced in July that it is requiring all transvaginal (TVM) mesh manufacturers to devote the next three years to post-market testing. The agency, however, appears unwilling to formally revoke approval of the mesh products, including Bard Avaulta mesh, for that indication. In practice, TVM mesh products—Bard mesh among them—have presented a myriad of health issues for women. For some patients, the mesh has affected intimacy with a spouse or partner. Ironically, with some patients for whom the Avaulta pelvic mesh was intended to resolve incontinence problems, symptoms of incontinence persisted. 